Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

August 21, 2015 updated by: Virginia G. Kaklamani, The University of Texas Health Science Center at San Antonio

Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers

Non-randomized, open-label, multi-center, phase I/II, dose-escalation study of the combination of carboplatin, eribulin, and E7449.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449. A cycle will be defined as 21 days. Carboplatin will be given on day 1 of each cycle. Eribulin will be given on days 1 and 8 of each cycle. E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.

Study Type

Interventional

Phase

  • Phase 2
  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Phase I only

  • Patients must have stage IV breast or ovarian cancer or another BRCA mutation-related cancer.
  • Patients may have either measurable or evaluable disease per RECIST 1.1 criteria.

NOTE: Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.

  • Patients must be refractory to / intolerant of established therapy known to provide clinical benefit for their condition.

Both Phase I & II

  • Patients must have archival biopsy specimens (preferably from metastatic disease) available for research tests. If a suitable biopsy specimen is not available, patients will be asked to undergo a research biopsy to procure tissue.
  • Patients must be ≥ 18 years.
  • Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation
  • Patients must have an ECOG performance status 0-1.
  • Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment for that cancer.
  • Patients must have normal organ and marrow function as defined below:

Leukocytes ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Creatinine within normal limits or creatinine clearance ≥30

  • Patients must be able to swallow and retain oral medication.
  • Patients who were receiving prior systemic therapy: Prior treatment related side effects must have resolved to < Grade 2 severity (except alopecia and infertility).
  • All patients must have given signed, informed consent prior to registration on study.

Phase II Only

  • Patients must have stage IV breast or ovarian cancer
  • Patients must have BRCA1/2 deleterious mutations, PTEN deficiency, or cancer with a high HRD score as assessed by Myriad's assay
  • Patients must have measurable disease per RECIST 1.1 criteria (see above for definition).
  • Patients may not have received more than 3 chemotherapeutic regimens for metastatic disease.
  • Patients who may not have received treatment with prior carboplatin, eribulin or a PARP inhibitor.

Exclusion Criteria:

  • Women who are pregnant or lactating are not eligible
  • Patients who are undergoing concomitant radiotherapy are not eligible.
  • Patients who are receiving any other investigational agents or concurrent anticancer therapy are not eligible.

NOTE: Previous systemic treatment is allowed with a 14 day (Phase I) or 21 day (Phase II) washout period prior to registration.

  • Patients who are taking any herbal (alternative) medicines are not eligible. Patients must be off any such medications by the time of registration.
  • Patients with known brain metastases are not eligible for participation unless the following are met:

Brain metastases are treated (either with surgical excision, stereotactic radiosurgery or radiotherapy and have been stable for at least 4 weeks (MRI documented) Patient is asymptomatic and has discontinued corticosteroids if taken for that purpose

Patients with any of the following conditions or complications are NOT eligible for participation:

GI tract disease resulting in an inability to take oral medication Malabsorption syndrome Require IV alimentation History of prior surgical procedures affecting absorption Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis). Hypersensitivity of any of the components of E7449, carboplatin, eribulin History of significant neurological (no neuropathy > Grade 2) or psychiatric disorders.

Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).

Significant non-neoplastic renal disease. Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).

Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) i.e., requiring relevant changes in medication within the last month or hospital admission within the last three months Active infection requiring systemic therapy. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment.

Prolongation of QTc interval to > 480 msec when electrolytes balance is normal. Major surgery within 4 weeks prior to the first dose of study drug

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Carboplatin, eribulin, and E7449
This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
Drug: Carboplatin
Carboplatin will be given on day 1 of each cycle.
Other Names:
  • Paraplatin
Drug: Eribulin
Eribulin will be given on days 1 and 8 of each cycle.
Other Names:
  • Halaven
Drug: E7449
E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
Other Names:
  • PARP inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of E7449 will be measured by the number, frequency and severity of adverse events.
Time Frame: Baseline to 24 months
Patients will be evaluated by MD at clinic visits during Cycle 1, on Day 1 of all 21-day cycles, and will have additional evaluations if clinically indicated.
Baseline to 24 months
MTD (maximum tolerated dose) of E7449 will be measured by the number, frequency and severity of adverse events.
Time Frame: Baseline to 21 days
Maximum tolerated dose (MTD) defined as highest dose studied in which the incidence of non-hematologic DLT (dose limiting toxicity) is defined as any Grade ≥ 3 toxicity, and a hematologic DLT is defined as any Grade ≥ 4 toxicity, both by CTCAE v 4.03 criteria.
Baseline to 21 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall response rate will be measured by the evaluation of target and non-target lesions for changes in tumor measurements.
Time Frame: Baseline to first occurrence of disease progression or death. (up to 6 weeks)
The overall response rate (ORR) will be defined as response after scans (CT or MRI) assessed after two cycles of therapy (1 cycle = 3 weeks).
Baseline to first occurrence of disease progression or death. (up to 6 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The University of Texas Health Science Center at San Antonio

Investigators

  • Principal Investigator: Virginia Kaklamani, UTHSCSA@CTRC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

April 1, 2015

Study Completion (Actual)

April 1, 2015

Study Registration Dates

First Submitted

February 10, 2015

First Submitted That Met QC Criteria

March 23, 2015

First Posted (Estimate)

March 24, 2015

Study Record Updates

Last Update Posted (Estimate)

August 25, 2015

Last Update Submitted That Met QC Criteria

August 21, 2015

Last Verified

August 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CTMS# 14-2024

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer of the Breast

Clinical Trials on Carboplatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe